In Vitro Diagnostic Product Demand to Exceed $24 Billion in 2016

US demand for in vitro (IVD) diagnostic products is forecast to increase 6.1 percent annually to $24.7 billion in 2016.  An expanding volume of patient care activity, spurred by aging demographic patterns, a rising incidence of diseases and disorders, and the extension of health insurance coverage by the Affordable Care Act of 2010, will underlie gains.  Advances in technology, along with the introduction of new and improved reagents and instruments, will drive up demand in most IVD product segments. These and other trends, including market share and product segmentation, are presented in In Vitro Diagnostics, a new study from The Freedonia Group, Inc., a Cleveland-based industry market research firm.  

Demand for clinical chemistry products will be boosted by uses in patient health screening and diabetes self-monitoring in addition to the widening availability of integrated and point-of-care systems offering greater productivity and operating ease.  The expansion of test menus for therapeutic drug monitoring, infectious disease detection, and cancer and cardiovascular testing, along with advances in chemiluminescent and other advanced systems, will promote gains in the US market for immunoassay products.  Companion diagnostics used to determine the safety and effectiveness of drug therapies will provide especially strong growth for immunoassay products.

Demand for molecular diagnostic products will grow the fastest among all IVD products due to their throughput, accuracy, and speed advantages in the detection of infectious diseases, tumors, and genetic disorders.  The US market for these products will benefit from the introduction of new, high value-added polymerase chain reaction (PCR) and related tests.  Demand for blood testing reagents and instruments will rise 3.4 percent per year to $2.6 billion.  Competition from new immunoassay and molecular tests will moderate growth in demand.  However, uses in pre-admission hospital testing, coagulation monitoring, donor matching, and donated blood screening will support gains.  Cellular analysis reagents and instruments will continue to generate sizable demand from uses in ovarian and breast cancer screening and HIV monitoring.  Demand for anatomical pathology reagents and instruments will expand well above the overall average growth pace of IVD products as clinical and forensic laboratories upgrade testing capabilities. 

The Freedonia Group is a leading international business research company, founded in 1985, that publishes more than 100 industry research studies annually. This industry analysis provides an unbiased outlook and a reliable assessment of an industry and includes product segmentation and demand forecasts, industry trends, demand history, threats and opportunities, competitive strategies, market share determinations and company profiles.